

Number 706 • October 2017

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the November 1, 2017, Updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at **https://www.ab.bluecross.ca/dbl/publications.html.**

Please refer to the November 1, 2017, Updates for complete listings of: products available by special authorization, products available by step therapy/special authorization, added products, new established interchangeable groupings, least cost alternative (LCA) price changes, products with a price change, discontinued listings and product(s) removed from the *ADBL* as Price Policy requirements not satisfied.

Please note that the online *Interactive Drug Benefit List (iDBL)* at **https://www.ab.bluecross.ca/dbl/idbl_main1.html** is a near real-time application and, as such, contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Verapamil SR 180 mg Sustained-Release Tablet (DIN 02450488) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **November 13, 2017.**

VERAPAMIL HCL

180 MG SUSTAINED-RELEASE TABLET

00002450488	MYLAN-VERAPAMIL SR	МҮР	\$ 0.5204
00001934317	ISOPTIN SR	BGP	\$ 1.6324

... continued from previous page

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortages of Sandoz Quetiapine XRT 50 mg Extended-Release Tablet (DIN 02407671) and Teva-Quetiapine XR 50 mg Extended-Release Tablet (DIN 02395444) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **November 16, 2017.**

QUETIAPINE FUMARATE

50 MG EXTENDED-RELEASE TABLET

00002407671	SANDOZ QUETIAPINE XRT	SDZ	\$ 0.3950
00002395444	TEVA-QUETIAPINE XR	TEV	\$ 0.3950
00002300184	SEROQUEL XR	AZC	\$ 1.0003

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.706 2017/10

